Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.

ABSTRACT:

Introduction

Efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, was demonstrated in randomised controlled trials; data on its real-world impact in routine clinical practice are starting to emerge. We assessed the effectiveness and safety of mepolizumab prescribed for patients in the real world.

Methods

REALITI-A is a global, prospective, observational cohort study, collecting data from routine healthcare visits from patients with asthma. Patients newly prescribed mepolizumab for severe asthma with 12 months of relevant medical history pre-mepolizumab (collected retrospectively) were enrolled. An initial analysis of data from early initiators who had completed 1 year of follow-up (as of February 28, 2019) was conducted. The primary objective was to compare th

SUBMITTER: Harrison T 

PROVIDER: S-EPMC7559868 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature